"Enhancing Large-Vessel Stroke Treatment: Methylprednisolone's Role Unveiled"

A randomized clinical trial involving 1680 patients with acute ischemic stroke due to large-vessel occlusion found that adjunctive intravenous methylprednisolone, when added to endovascular thrombectomy, did not significantly improve overall disability at 90 days. However, the methylprednisolone group showed lower mortality rates and a lower incidence of symptomatic intracranial hemorrhage compared to the placebo group. The study suggests that while methylprednisolone did not significantly improve disability outcomes, it may have potential benefits in reducing mortality and intracranial hemorrhage in this patient population.